In today’s episode, we will be discussing why Psychedelic Stocks, like MindMed (MMED / MMEDF) and Compass Pathways (CMPS) are not Cannabis 2.0, and why psychedelic stock prices will not follow the same path. For those who remember, Pot Stocks skyrocketed on the news of legalization, and then quickly tumbled back down to earth.

Some have dismissed companies like MindMed (MMED/MMEDF) and Compass Pathways (CMPS) as just the cannabis hype 2.0.
This, however, could not be further from the truth.
To be clear stocks like, MindMed Stock ( MMED : NEO market) and (MMEDF : OTC market), and Compass Pathways stock, ticker symbol CMPS are nothing like cannabis stocks.
To explain why, we are going to discuss an article entitled , “Why The Psychedelics Market is not Cannabis 2.0”, written by Jeff Siegel.

Psychedelic stocks are comparables to biotech companies these days. The prospect of promising research is pushing valuations upwards There are plenty of psychedelic stocks have experienced triple-digit returns in the last twelve months:

MindMed Stock MMED/MMEDF): 864%
Numinuss Wellness (NUMI): 555%
Revive Therapeutics (RVV): 166%
Compass Pathways (CMPS): 88%

The psychedelic industry is only just commencing. Other psychedelic stocks will soon penetrate the market and early investors can benefits from the shroom boom with 10X to 20X gains.

#psychedelicstocks #shroomstocks #mindmedstock

https://www.benzinga.com/markets/cannabis/21/01/19008810/why-the-psychedelics-market-is-not-cannabis-2-0

Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

Similar Posts

MindMed’s Q2 Earnings Call: What does the future hold for MNMD/ MMED?

MindMed’s Q2 Earnings Call: What does the future hold for MNMD/ MMED?

Listen, Videos

Check out atai Life Sciences’ earnings call: https://www.youtube.com/watch?v=lkE3EmU0o_w

What’s up psychedelic stocks investors?!? Today marked MindMed’s (MNMD /MMED) Second Quarter 2021 conference call. In the conference call, MindMed gave updates on their varying projects, such as treating anxiety with LSD, addiction with 18MC, and pain with LSD. They also give insights into their digital medicines division and gave an update on their hiring spree.

This Kevin O’Leary-backed psychedelic therapies company is fighting for the title of the most advanced psychedelic stock. With 17+ different projects under their belt, MindMed is one of the most exciting companies to keep an eye on in the industry.

This conference call can help investors answer the questions: is MNMD stock a good investment? Will MMED go up? Are psychedelic stocks / shroom stocks good investments? Can psychedelics heal depression? Can psychedelics be used for mental health?

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Check out our website: thepsychedelicinvestor.com

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

#MindMed #MNMD #PsychedelicStocks

Interview with Matt Zemon, Co-Founder, Psychable

Interview with Matt Zemon, Co-Founder, Psychable

Listen, Podcasts

In our conversation with Matt, we tackle a variety of extremely important and highly-relevant subject matters such as how technology can be utilized to enhance the community of psychedelic healing, conscious capitalism, corporate responsibility, and how companies like Psychable are willing to go out of their way to connect with investors who are motivated not only by profit, but a company’s ability to contribute to the greater good of humanity.

Why the SHROOM BOOM Isn’t Just About Psychedelic Mushrooms

Why the SHROOM BOOM Isn’t Just About Psychedelic Mushrooms

Learn, Videos

How mushrooms are taking over the healthcare industry, and how investors can profit off of this. First we will talk about how they are being used as treatments for mental health conditions. And then we will talk about how regular, non psychedelic mushrooms are being used to promote healthy lifestyles, and perhaps even lengthen lifespans and increase quality of life.
The psychedelic craze has overshadowed another important facet of mushrooms and the Shroom Boom.
The health benefits and investing opportunities of non-psychedelic mushrooms.
Fungi like Lion’s Mane, Chaga and reishi have a variety of health benefits, and have recently been labelled as superfoods.
For example, Reishi mushrooms, which have been “revered in Asian societies for thousands of years”, have antibacterial, antiviral, and anti-fungal characteristics, and is high in proteins and vitamins.
While this is great news for you health, and I personally incorporate mushroom extracts into my diet, on this channel we also focuses on investing.
According to the Grand View Research Corporation, the global mushroom market, not including the psychedelic variety, is set to grow to an eye watering $50 billion annually by 2025.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

The Psychedelic Investor was compensated $1,000 by Future Money Trends for the having the interview with PlantX CEO. James (The Psychedelic Investor) does not own a position in PlantX and will not open one for at least 30 days after publication of this video.

Full Disclaimer
https://www.goldstandardir.com/plantx-life-disclaimer-85/

#ShroomBoom​​​ ​#PlantX​​​ #PsychedelicStocks

Interview with Dr. Erica Zelfand

Interview with Dr. Erica Zelfand

Listen, Podcasts

This week on the Psychedelic Spotlight podcast, we’re chatting with Dr. Erica Zelfand. She is a family doctor specializing in integrative and functional family medicine. She’s also a ketamine prescriber, facilitator of therapeutic experiences, and a medical writer and public speaker.